Here’s a number that should make every state budget office sit up straight. Tennessee restricted major hemp product categories in July. The state had projected roughly $9.4 million in hemp sales-tax collections for that month. Actual collections: about $425,000. That’s a miss of more than 90 percent, and if the pace holds, the annual hole could top $110 million.
For years, cannabis debates lived in the morality department. Should weed be legal, is hemp a loophole, do people belong in jail for it. Those questions still exist, but this weekend’s news lives somewhere politicians pay much closer attention: the financial statements. Michigan’s Republican nominee for governor is saying the state overtaxed its own legal market. South Dakota regulators are begging Washington for an instruction manual on rescheduling. And nearly 900 Missourians are chasing 77 licenses in a program still learning that a license and a viable business are two very different things.
None of this is really about cannabis culture. It’s about capital allocation, tax policy, regulatory certainty, and whether government can actually run the market it created. An industry becomes hard to prohibit once prohibition has budget consequences, and hard to overtax once legal businesses start closing. Cannabis spent years demanding legalization. Now it’s forcing a much less ideological question: can you run the thing you built? Let me walk you through it.
Missouri got nearly 900 applications for 77 licenses, and the lottery is the easy part.
Missouri’s social-equity experiment is entering its final round, and demand is enormous. State regulators received close to 900 applications for the third and final round of marijuana microbusiness licenses, with just 77 available and the Missouri Lottery drawing winners September 9. The program came out of the 2022 voter-approved legalization amendment, built to give smaller and historically excluded entrepreneurs a path into cannabis without needing multistate-operator scale.
On paper, simple. In reality, messy. The first two rounds produced ownership disputes, compliance problems, and multiple license revocations tied to arrangements regulators concluded violated the majority-ownership requirements. So the state tightened up, reviewing ownership structures before issuing licenses instead of discovering shell games afterward, communicating directly with majority owners instead of their consultants, and requiring more compliance education.
That sounds procedural. It goes straight at social equity’s biggest unsolved problem: who actually owns the business? Cannabis licenses can be enormously valuable, and a qualifying applicant may check every statutory box while lacking the millions needed to open. Enter the capital partner, offering funding, expertise, property, and buildout, in exchange for control, economics, and management rights, sometimes so much control that the “majority owner” exists mostly on paper.
Banning exploitative deals doesn’t solve the capital gap. It just means the qualifying owner keeps control of a business that still can’t afford to open.
The stat that matters most: as of August 18, Missouri had 21 operating microbusinesses, five dispensaries and 16 wholesalers, with another 46 licenses active but not yet approved to operate. One early licensee, Jimi Poe, said opening took roughly two years instead of the six months he expected, and when he finally opened, his dispensary carried just nine strains because the microbusiness supply chain was so thin. That’s why these programs should be measured by operating outcomes, licenses opened, capital raised, businesses still majority-controlled, jobs, revenue, three-year survival. Anything less confuses regulatory permission with entrepreneurship.
The bottom line: Nearly 900 applicants prove the demand is real. But social equity doesn’t succeed when someone wins a license. It succeeds when that person still owns and operates a viable company years later.
Tennessee’s hemp ban may have blown a $110 million hole in the budget.
Tennessee wanted less hemp THC. It’s getting a lot less tax revenue too. The state began enforcing restrictions in July that banned major cannabinoid categories, including smokable hemp and THCA products that industry groups say made up as much as 75 percent of the market. Then the first month of tax data landed: $425,000 collected against a $9.4 million projection, a miss of more than 90 percent. Annualized, the gap could exceed $110 million. And this was already a shrinking number, since the state had cut hemp projections by $55 million the prior year and still finished about $55.8 million under.
Fair caveats first: one month doesn’t make a fiscal year, consumer behavior can shift, compliant products could gain share, collections could recover. But the early data illustrates something policymakers chronically underestimate.
When government bans a legal product category, it isn’t just changing criminal or health policy. It’s changing a tax base. And tax bases don’t ask permission before they leave.
Democratic lawmakers are already weaponizing the numbers, with Rep. Aftyn Behn and Sen. Heidi Campbell pushing their “pot for potholes” plan, legal adult-use cannabis with a 15 percent tax pointed at the state’s road backlog. Whether voters want that is a separate question. The more interesting one is: where did the hemp consumer go? If they quit entirely, the policy cut both consumption and revenue. If they moved to untaxed illegal marijuana, the state lost the money and pushed customers outside the regulated system. If they shifted to other legal products, the taxes may resurface elsewhere. That substitution data decides whether the crackdown actually worked. And don’t miss the private-sector shadow of these numbers, because a 90-percent sales collapse means retailers losing revenue, which means layoffs, closures, lease defaults, and loan stress. The government just feels the same shock later, through the treasury.
The bottom line: Prohibition now comes with a measurable price tag. A state can pull a legal product off shelves, but it can’t collect sales tax from a transaction that moved underground.
South Dakota says rescheduling arrived without an instruction manual.
Federal medical-marijuana rescheduling was supposed to create clarity. South Dakota says it created a new category of questions. State medical-cannabis administrator Whitney Brunner told lawmakers that since medical marijuana moved to Schedule III in April, Washington has requested information from the state but provided remarkably little implementation guidance. Her summary: officials still have more questions than answers.
That matters because the benefits at stake are enormous. Schedule III should free medical operators from Section 280E and improve banking access, and for a cannabis CFO those changes ripple through effective tax rates, free cash flow, debt coverage, valuation, and expansion economics. But “should help” isn’t a phrase a bank can underwrite.
A lender needs the details. Does every state medical operator qualify automatically? Is DEA registration required? What inspections? How do you separate qualifying Schedule III revenue from activity that’s still federally prohibited? “Congratulations” is not an operating manual.
Some businesses are pushing ahead anyway. Kittrick Jeffries, who chairs the state’s industry association and owns Puffy’s Dispensary, says multiple member businesses are already going through DEA inspection and licensing. That’s encouraging and alarming at once, encouraging because operators are preparing for federal integration, alarming because they’re spending compliance money before anyone knows the final requirements. Meanwhile South Dakota’s own program is reforming after admitting its inspections were inconsistent, adding training, supervision changes, formal appeals, and possibly lighter penalties for minor first offenses. One operator said a $3,000 penalty for two clerical errors forced him to postpone other spending, which connects the whole story: compliance costs consume capital, and ambiguous compliance consumes even more. You can budget for a clear inspection requirement. You can’t budget for a mystery.
The bottom line: Schedule III may materially improve medical-cannabis economics, but financial normalization takes more than changing one line of the Controlled Substances Act. Banks, businesses, and states need an operating manual, not another headline.
Michigan’s GOP nominee wants lower weed taxes and tighter hemp rules, and that combo is the future.
Michigan’s Republican nominee for governor, John James, has a cannabis platform that would’ve sounded bizarre a few years ago. He wants to repeal or sharply cut the state’s new 24 percent wholesale cannabis tax, while restricting intoxicating hemp products sold outside the licensed marijuana market. And notably, he’s not running against legalization at all, he explicitly says voters approved the 2018 market and government should respect that. His argument is that Michigan is undermining its own legal system through excessive taxation and lopsided competition.
The math backs him up. The 24 percent wholesale levy stacks on top of a 10 percent excise tax and 6 percent sales tax, and the cumulative burden pushes legal prices up while illegal sellers pay nothing. The state projected roughly $420 million from the tax for roads, Republican lawmakers have already filed repeal legislation, and companies are challenging it in court. Now it’s a governor’s race issue.
Cannabis-tax relief isn’t being framed as a progressive legalization cause anymore. It’s a small-business, free-market argument: tax the legal operator too hard and you hand the illegal one a pricing advantage. That travels across party lines.
His hemp position is the other half of the same worldview. He says delta-8, THCA, and synthetic cannabinoids shouldn’t sell through gas stations and smoke shops without the age limits, testing, and labeling that licensed marijuana faces. That’s regulatory parity, if it intoxicates like cannabis, regulate it like cannabis. And that concept is rapidly becoming the political center: not prohibition, not anything-goes hemp, but regulated marijuana, regulated intoxicating cannabinoids, real enforcement against illegal sellers, and lower unnecessary costs for rule-followers. Licensed operators love it. Independent hemp businesses see an attempt to force them into a far more expensive channel. Both readings have merit, and the long-term question is whether product risk or plant definition ends up determining regulation. Michigan suggests risk is winning.
The bottom line: Pro-cannabis-business no longer means pro-every-cannabinoid. The emerging center is lower taxes for licensed operators, stricter standards for intoxicating hemp, and tougher enforcement against everyone outside the system.
Iowa is opening medical cannabis to out-of-state patients, starting with Nebraskans.
Iowa’s medical program is starting to cross state lines. Regulators filed proposed rules removing the residency requirement for qualified patients, following legislation Governor Kim Reynolds signed in June, and restoring reduced registration fees for veterans. The obvious beneficiaries are Nebraskans, since regulators specifically note Nebraska is the only neighboring state without an operational medical or adult-use program. A Nebraska patient could get certified by an Iowa provider and register in Iowa’s program.
Small regulatory change, potentially large implications. Cannabis policy has always been chained to geography, and the absurdity is easy to state.
A medical patient in one state can legally access cannabis. A patient with the identical diagnosis fifteen miles away cannot. The medical need doesn’t change at the border. Only the law does.
Iowa is starting to weaken that distinction, and the same legislation doubled its authorized dispensaries from five to ten to fix geographic access complaints. The program reports 17,741 patients and 524 caregivers, and regulators don’t expect a massive influx, partly because Iowa’s program stays genuinely restrictive: a 4.5-gram THC purchase limit over 90 days for most patients, with smoking and flower prohibited. So this isn’t cannabis tourism, it’s a controlled medical pathway for people with no functioning program at home. For dispensaries near the border, though, the potential service area just changed, and lenders evaluating those businesses should assess patient counts beyond state population alone, because cross-border medical access reshapes trade areas the same way neighboring adult-use markets reshape recreational retail. And the veteran fee fix, restoring a $25 application fee instead of $100 after the language got accidentally deleted in a red-tape review, is small but worth doing. Cannabis regulation has plenty of hard questions. Un-botching a $75 mistake for veterans isn’t one of them.
The bottom line: Iowa is starting to treat medical cannabis like healthcare instead of a residency privilege. A diagnosis doesn’t change when you cross a state line, and programs are slowly beginning to admit it.
Texas hemp operators say the state destroyed jobs without ever changing the law.
Texas’s hemp crackdown is facing another federal lawsuit. Four retailers are challenging the Department of State Health Services, arguing regulators exceeded their authority by classifying broad categories of hemp-derived THC products as illegal, effectively changing policy through executive interpretation rather than legislation. They’re seeking immediate relief and making dramatic economic claims, tens of thousands of job losses, collapsed sales, billions in damage. Important flag: those figures are the plaintiffs’ claims, not judicial findings, and should be read that way.
But the underlying legal issue matters regardless of the final numbers. Businesses built an entire retail ecosystem around their understanding of the 2018 Farm Bill and Texas hemp law, stores, leases, inventory, employees, brands, and then regulators concluded multiple compounds belong in prohibited categories.
This is the scenario lenders fear most. The borrower didn’t become incompetent, demand didn’t vanish, the location didn’t decay, nobody committed fraud. The rules changed. Regulatory risk destroyed credit quality without any conventional deterioration in the business.
That should reshape how banks analyze cannabinoid companies: break revenue down by product category, ask which cannabinoid generates the margin, what percentage rides on disputed legal interpretations, what revenue looks like if one category disappears, how much inventory becomes unsellable, whether the lease and debt survive. Those questions belong in underwriting now. The lawsuit also alleges Texas’s interpretation conveniently benefits the state’s medical-marijuana system by eliminating competing hemp products, again an allegation, not a finding, though removing one channel obviously strengthens the remaining ones. And it all circles back to transition periods. Even if Texas ultimately has the authority, inventory bought under one legal interpretation doesn’t magically vanish, and neither does the debt, payroll, or rent attached to it. If a state believes a product is risky enough to prohibit, the policy analysis should include the cost of shutting the legal market down and what the consumer does afterward.
The bottom line: Texas is a national test of how much regulatory instability cannabis businesses are expected to absorb. A market can’t attract normal capital if the legality of its core inventory changes faster than the loan that financed it.
The DEA is fixing a 2,470-page transcript, and that boring work might protect 280E relief.
Federal rescheduling has reached its least glamorous stage: correcting the record. DEA Chief Administrative Law Judge Derek Julius ordered dozens of changes to the official rescheduling hearing transcript, which runs roughly 2,470 pages, with a corrected version due August 26. Many fixes are names and transcription errors. Some change the meaning of testimony in more material ways.
Here’s why the cleanup matters more than it looks. Administrative decisions are built on the record, and the judge’s recommendation has to rest on the testimony, exhibits, and arguments developed in the proceeding. A sloppy record hands opponents more angles to challenge the outcome.
For an industry impatient for rescheduling, the procedural crawl feels maddening. But a fast rule that gets overturned is worth less than a slow rule built on a defensible record. In cannabis, the most valuable paperwork is the paperwork that keeps 280E relief from getting reversed.
Meanwhile, the substance of DEA’s position remains remarkable on its own. The agency is defending the move to Schedule III, arguing marijuana no longer satisfies Schedule I’s requirements, pointing to widespread medical use and a lower abuse profile than the most restricted drugs. Federal regulators once said cannabis had no accepted medical use. The government’s own record now includes millions of patients and tens of thousands of practitioners. The law is catching up to reality. For the industry, the headline stays the same, a broader Schedule III move could pull marijuana out of 280E’s reach, and a company that looks marginal under 280E can look dramatically healthier once ordinary deductions return, better cash flow, better debt coverage, higher enterprise value. But banks shouldn’t underwrite as if the most favorable outcome is guaranteed. Run the scenarios: current treatment, Schedule III, delayed implementation, litigation. Cannabis finance still requires multiple cases.
The bottom line: The transcript cleanup looks painfully bureaucratic. It may be exactly what durable reform requires, because the biggest tax change in industry history is only valuable if it survives the appeals.
You can be legal enough to buy medical cannabis and illegal enough to go back to jail for it.
Cannabis legalization has produced a strange category of American: someone following one law while violating another. A patient has a qualifying condition, a physician authorizes cannabis, the state issues a card, the patient buys a regulated product from a licensed dispensary. Then their probation conditions say no marijuana. A Reason Foundation opinion piece in Marijuana Moment highlights how common that trap remains for people under supervision.
The scale is bigger than most people realize. Nearly four million Americans are on probation or parole, and some state systems still prohibit marijuana even when the person could legally participate in a medical program. A positive drug test becomes a technical violation, which can trigger sanctions or reincarceration. The piece cites estimates that states spend billions reincarcerating people for technical violations like missed appointments and positive tests, though it concedes the data doesn’t isolate how many involve marijuana specifically. It’s an opinion article, so read the recommendations as advocacy. But the contradiction it identifies is real.
Medical marijuana laws were layered on top of older systems, not swapped in for them. Probation, employment, housing, licensing, firearms, family court, immigration, all coded for prohibition. Call it legalization debt: the headline law changed, and everything downstream still runs the old software.
Federal rescheduling makes the contradiction harder to defend, because if the federal government recognizes accepted medical use, states eventually have to explain why a supervised person taking physician-authorized cannabis is automatically treated differently from someone on any other medication. That doesn’t mean unrestricted access for everyone under supervision, a judge may have individualized safety reasons for conditions. But individualized restriction and blanket prohibition are different things. And the economics are quietly relevant too, since every collateral consequence, employment testing, housing rules, probation conditions, shrinks the pool of people willing or able to participate in legal markets.
The bottom line: Legalization isn’t complete when the dispensary opens. It’s complete when the rest of government stops punishing people for activity the state itself authorized. The next reforms will involve cleaning prohibition out of laws that don’t look like cannabis laws at all.
Closing Thoughts
For a long time, bad cannabis policy had invisible economic consequences. Ban marijuana, people bought it illegally anyway, government never collected the taxes to begin with, banks stayed away, and there wasn’t much regulated activity to destroy. That era is over.
Tennessee proves it beautifully. The state restricted a large legal product category, and one month later, the budget noticed. Not activists, not dispensary owners. The budget. That’s how cannabis becomes politically durable, not because every politician suddenly likes weed, but because prohibition starts creating line items: lost revenue, lost jobs, empty retail space, stressed loans. Then government has to evaluate policy like economics instead of ideology. Michigan is running the same calculation from the other direction, with a Republican nominee arguing the regulated market got too expensive, cut the tax, enforce against illegal sellers, and pull intoxicating hemp into a comparable framework. That’s a very different conservative cannabis position than a decade ago.
Missouri exposes the maturation problem inside social equity. Everyone loves announcing licenses. Almost nobody wants to discuss how much capital it takes to turn paper into a functioning dispensary, and if that capital is missing, the license isn’t wealth, it’s an expensive obligation. Missouri’s new ownership rules rightly target predatory arrangements, but the harder problem remains: how do you get qualifying owners capital without handing away control? South Dakota shows the opposite end, where a genuinely good federal reform arrived without an operating manual, and businesses are spending compliance money on guesswork. Iowa offers the rare story of government just removing friction, since a state border doesn’t change a diagnosis. And Texas is the warning that capital requires confidence the rules will outlive the investment, because when the legality of core inventory can flip every six months, that risk gets priced somewhere, higher rates, lower valuations, less investment, and eventually the consumer pays.
The contradictions in today’s edition, one cannabinoid regulated like marijuana and another like hemp, one state banking on hemp taxes while another erases the market, patients legal enough to buy medicine but not legal enough to consume it, were tolerable when cannabis was small. Cannabis isn’t small anymore. The industry is now big enough that bad regulation leaves receipts, and once government starts receiving those receipts, in tax shortfalls, lawsuits, and bankrupt businesses, the debate changes permanently. It stops being “do we like marijuana?” and becomes “which system actually works?”
That’s what this newsletter is for.
What’s the biggest regulatory challenge your operation is facing right now? Hit reply, I read every response and it shapes what I cover next week.
If this was useful, forward it to someone in the cannabis space or hit the restack button on Substack. It’s how this community grows.